- $8.72m
- -$10.26m
- 18
- 44
- 28
- 19
Annual income statement for Mustang Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 56.8 | 66.7 | 76.2 | 49.3 | 16.2 |
| Operating Profit | -56.8 | -66.7 | -76.2 | -49.3 | -16.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -60 | -66.4 | -77.5 | -51.6 | -15.8 |
| Net Income After Taxes | -60 | -66.4 | -77.5 | -51.6 | -15.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -60 | -66.4 | -77.5 | -51.6 | -15.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -60 | -66.4 | -77.5 | -51.6 | -15.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -856 | -566 | -562 | -308 | -19.8 |